Twenty-eight of @ participants in a prospective @-year clinical trial of OctLAR ( @ mg monthly ) consisting of double-blind , randomized ( year @ ) and open-label treatment ( year @ ) phases reenrolled in a @-year open-label extension ( OLE ) study after being off OctLAR a mean of @ months ( original study : July @ , @ , through June @ , @ ) .